Drug Profile


Alternative Names: 06-BG; Alkylade; BG; KRX 0402; NSC 638037; O6-benzylguanine

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA); The Pennsylvania State University
  • Developer ACCESS Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Chemosensitisers; Hypoxanthines; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cutaneous T cell lymphoma
  • Discontinued Brain cancer; Glioblastoma; Glioma; Multiple myeloma; Sarcoma

Most Recent Events

  • 01 Feb 2017 National Cancer Institute completes a phase-I/II clinical trial in Cutaneous T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT00961220)
  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2004 ACCESS Oncology has been acquired by Keryx Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top